Amlozaar

Quick links to important sections

Amlozaar

Method of action: Antihypertensive

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amlozaar

Property Description
Active Ingredients Amlodipine and Losartan
Form Oral Tablets (Fixed-Dose Combination)
Pharmacological Class Antihypertensive Agent (CCB + ARB)
Common Use Blood pressure lowering
Origin Synthetic

Amlozaar is a foundational cardiovascular medicine defined by its combined composition and dual action intended for the systemic administration of blood pressure lowering. It is available as a prescription-only oral tablet and is classified as a fixed-dose combination (FDC) product, containing two distinct, synthetic antihypertensive agents.

What Type of Medicine is Amlozaar?

Amlozaar is an antihypertensive agent that delivers two separate active substances in a single oral tablet. It is classified as an FDC, merging a Calcium Channel Blocker (CCB) and an Angiotensin II Receptor Blocker (ARB), which are two different classes of drugs used to manage high blood pressure. This formulation is designed to engage two distinct biological mechanisms simultaneously, a strategy that is clinically recognized for optimizing patient adherence compared to taking the two components separately. The combination of Amlodipine (CCB) and Losartan (ARB) is a standard treatment strategy for hypertension, established as a method for regulating elevated blood pressure.

Amlozaar's Composition: A Dual-Action Formulation

The medication is composed of the active ingredients Amlodipine and Losartan. Amlodipine, often formulated as the besylate salt, and Losartan, typically used as the potassium salt, are both small molecule, synthetic compounds. The dual approach provides a synergistic effect, as each component targets a different physiological pathway contributing to elevated blood pressure. The co-administration of agents with complementary mechanisms is a recognized strategy in treating hypertension, as combining these two agents is a logical method for achieving blood pressure control.

What is the General Purpose of Taking Amlozaar?

The primary purpose of using Amlozaar is to achieve effective and sustained blood pressure lowering. This is accomplished through its dual mechanism of action: Amlodipine promotes the relaxation and widening of the blood vessels (vessel relaxation), while Losartan acts by blocking the hormonal signals (Angiotensin II) that cause vessels to constrict (hormonal system blockade). This combined, targeted effect reduces resistance within the circulatory system, easing the workload on the heart. A typical neutral use scenario involves managing high blood pressure in adult patients whose blood pressure has not been adequately controlled by a single agent alone.

Regulatory References

  1. NIH MedlinePlus Drug Information

What side effects are possible with Amlozaar?

Possible Side Effects and Safety Information

The official safety profile for Amlozaar, a fixed-dose combination of Amlodipine and Losartan, describes possible adverse reactions using established frequency classifications and System-Organ Classes (SOC), as mandated by regulatory authorities like the EMA and FDA. The effects are primarily related to the actions of its two components.


Frequency-Classified Adverse Reactions

Adverse reactions that are documented as Very Common (ge 1/10) include headache and edema (swelling), with edema being a known dose-related effect of the Amlodipine component. Reactions classified as Common (ge 1/100 to < 1/10) generally involve the Nervous System (dizziness, somnolence) and systemic effects (fatigue, palpitations, nausea).


Serious Adverse Reactions and Safety Constraints

Specific serious adverse reactions are documented, including the potential for Angioedema (severe allergic swelling) associated with the Losartan component. The label also notes the risk of worsening angina or myocardial infarction in susceptible patients following the initiation or dose increase of Amlodipine. The medication carries explicit safety constraints and is contraindicated in the second and third trimesters of pregnancy due to the risk of injury or death to the developing fetus, which is associated with the Losartan component.


Population-Specific and Time-Related Notes

The safety profile includes specific considerations for certain populations. Patients with severe hepatic impairment or certain pre-existing conditions (e.g., bilateral renal artery stenosis) require particular caution. The Losartan component necessitates monitoring for hyperkalemia (elevated potassium) in patients with renal impairment. Furthermore, some adverse effects, such as dizziness and headache, are often reported as more frequently observed at the start of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Amlozaar is officially documented as primarily affecting the cardiovascular system, potentially leading to severe and prolonged systemic hypotension (profound low blood pressure) resulting from excessive peripheral vasodilation. Key clinical manifestations listed in regulatory documents include marked hypotension, dizziness, and somnolence (drowsiness), often accompanied by reflex tachycardia (fast heart rate).

This condition can escalate to life-threatening outcomes, including circulatory collapse and shock. Because of the risk of profound hypotension and potentially fatal outcomes, immediate medical attention must be sought upon known or suspected excessive ingestion. Urgent engagement of emergency services is required if the patient exhibits signs of severe or prolonged low blood pressure.

Management is described as symptomatic and supportive treatment, as official labeling states that no specific antidote is known. Clinical procedures involve continuous monitoring of vital signs and cardiac function. Due to the prolonged duration of the drug’s effects, an extended observation period in a clinical setting is typically required.

Therapeutic Uses of Amlozaar

What Amlozaar Treats: Main Uses and Benefits

Managing Chronic Elevated Blood Pressure

The primary therapeutic domain of Amlozaar is the sustained control of high blood pressure (essential hypertension). It is commonly used in adults to address the chronic, elevated pressure exerted on arterial walls, relevant in conditions characterized by periods of heightened symptoms, such as moderate or Stage 2 hypertension. The medication is used in clinical settings where supportive symptom management is appropriate. The primary benefit for the patient is support that helps ease the overall symptom burden of high pressure, which contributes to maintaining functional stability.


Long-Term Cardiovascular and Organ Protection

Amlozaar is applied across domains where additional symptomatic support is needed to address recurrent cardiovascular risk factors, playing a role in managing symptoms related to systemic imbalance. The medication is considered relevant for use in conditions characterized by periods of heightened symptoms, including hypertension, chronic stable angina, and the management of cardiovascular risk. In situations where patients experience concurrent conditions like Type 2 diabetes, the medication may assist with managing the risk of organ-specific functional stress.


Supportive Relief for Angina-Related Symptoms

The medication is also relevant in clinical contexts that involve ischemia-related chest discomfort. It can be used for the supportive management of symptoms associated with chronic stable angina. This may assist with maintaining functional stability and supports general well-being during symptomatic phases.

Quick Fact: Support for Sustained High Blood Pressure Management
Amlozaar is used for managing the symptoms related to heightened physiological activity associated with chronically elevated systemic pressure, assisting with maintaining functional stability.

Eligibility and Restrictions for Use

Amlozaar (Losartan/Amlodipine) is defined by regulatory bodies as being restricted to specific patient groups, while its use is strictly prohibited for others.

Contraindications (Must Not Use)

Classification Patients Excluded
Absolute Hypersensitivity to Losartan, Amlodipine, or formulation components.
Pregnancy (2nd and 3rd trimesters), and nursing/breastfeeding mothers.
Patients with severe hepatic impairment.
Patients with cardiogenic shock, severe hypotension, or significant aortic stenosis (Amlodipine component).
Diabetic or renally impaired patients (GFR < 60 mL/min) taking aliskiren.

Eligibility-Related Restrictions (Use with Caution)

  • Pediatrics: Use is generally not recommended for children under 6 years old, as safety and efficacy have not been established. Use in older children is not recommended if they have underlying renal or hepatic impairment.
  • Organ Function: Patients with a history of hepatic impairment (not severe) may require a lower starting dose. Caution is required for patients with volume depletion (which must be corrected prior to use) or renal artery stenosis.
  • Special Populations: Official data recommend not using the medicine in patients with primary hyperaldosteronism or those with severe heart failure (NYHA Class IV) due to insufficient therapeutic experience.

What should I know about interactions with other medicines?

The interaction profile for Amlozaar is defined by the regulatory classification of its two active components, Amlodipine and Losartan, and is based exclusively on official government documentation.

The Losartan component is involved in a contraindicated combination with Aliskiren for patients with diabetes mellitus due to documented risks of severe renal and cardiovascular outcomes.

Documented Pharmacokinetic Outcomes

Co-administration with strong CYP3A inhibitors (e.g., Ketoconazole) significantly increases the systemic exposure of Amlodipine. This pharmacokinetic outcome requires patient monitoring. For co-administered medicinal products, the dose of Simvastatin must be limited to 20 mg daily to mitigate the risk associated with Amlodipine-mediated increases in Simvastatin exposure.

Pharmacodynamic Risks and Restrictions

Use with Potassium-sparing diuretics and Potassium supplements is officially not recommended due to a documented risk of hyperkalemia via the Losartan component. Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may result in the attenuation of the blood pressure lowering effect and an increased risk of worsening renal function.

Alcohol (Ethanol) may contribute to additive hypotensive effects. Clearance of both active components is reduced in patients with hepatic impairment, which increases overall systemic exposure and potential interaction sensitivity.

Mechanism of Action

How Amlozaar Works

The drug operates through a dual-mechanism approach that influences two primary systems governing blood vessel tone and fluid balance, resulting in modulated activity within the circulatory system.


Modulating Vascular Muscle Contraction

One component of the drug acts as an inhibitor of L-type voltage-gated calcium channels on the arterial muscle walls

. By blocking the influx of calcium ions, the drug prevents the necessary molecular signal for smooth muscle contraction. This action initiates a cascade that leads to the widening and relaxation of the blood vessels (vasodilation), decreasing systemic vascular resistance.


Interrupting Hormonal Signals

The second component of the drug functions as a selective antagonist of the Angiotensin II Type 1 ( AT1) receptor

. By blocking this receptor, the drug suppresses the vasoconstrictive and volume-retaining signals normally generated by the hormone Angiotensin II within the Renin-Angiotensin-Aldosterone System (RAAS). This targeted pathway adjustment supports vessel relaxation and promotes natriuresis and diuresis, influencing circulating fluid volume and vessel wall tension.

Dosage and Administration Information

The Amlodipine/Losartan fixed-dose combination, referred to as Amlozaar, is administered strictly via the oral route as a film-coated tablet. The fundamental principle of its usage is a sustained, long-term regimen to manage chronic blood pressure elevation.

The medicine is used following a specific daily schedule and dosing protocol:

Administration Feature General Instruction
Dosing Frequency The tablet is taken once daily (q.d.).
Dosing Range Usual initial dosing often begins with the lowest available strength (e.g., 5 mg Amlodipine / 50 mg Losartan), with a maximum daily dose not exceeding 10 mg Amlodipine / 100 mg Losartan.
Timing & Food The tablet may be taken with or without food and should ideally be taken at the same time each day for consistency.
Titration Interval Dose increases are typically separated by an interval of 1 to 2 weeks to allow for the assessment of the patient's response to the current dose level.

The tablet must be swallowed whole and should not be crushed or chewed, as its integrity is important for proper delivery. If a dose is missed, the standard protocol is to omit the missed dose and resume the normal schedule the following day; a double dose should not be taken.

In certain populations, a lower starting dose of the individual components may be necessary. For instance, a lower dose of the Losartan component is generally considered for patients with mild-to-moderate hepatic impairment, and a reduced Amlodipine dose (e.g., 2.5 mg) may be appropriate for small, fragile, or older adult patients. This adherence to a structured, once-daily, and orally intact administration defines the protocol for its use.

Recent Clinical Evidence

Amlozaar: Recent Clinical Evidence


Research Evidence / Overview of Studies

Mechanism of Action

This section summarizes how research has explored the drug's activity and the key findings and evidence gaps from studies.

Research begins by examining the drug's activity in the central nervous system. Studies then investigated whether the drug's activity related to observed differences in the participants' reported anxiety and mood.

Evidence for Core Indication

Clinical trials were conducted to examine outcomes in the studied adult population.

  • The primary finding related to differences in symptom severity scores recorded over the 6-month study period.
  • Data were collected regarding the time when effects were first observed in participants.
  • Long-term data extending to one year were examined to track data patterns.
  • Some research included comparisons to other approved treatments.

Evidence for Secondary Indications

Research has also examined whether the drug has an associated effect on related conditions such as generalized mood dysregulation.

A key finding from studies is that there was an observed reduction in the frequency of flare-ups in a sub-group of study participants.

Combination Therapy Studies

Furthermore, a separate study examined whether combining the drug with therapy was associated with changes in quality of life scores. The evidence remains limited, and further research is needed to determine the relevance of this observation.

Studies have evaluated whether taking the drug consistently was associated with different outcomes.

Safety and Tolerability Findings

Side effects were recorded in the studies, and researchers have examined long-term use. Specific populations, such as those with a history of heart conditions, were generally excluded from or had limited participation in the primary studies. Research did not address what patients might do if symptoms worsen.

Key Studies & References

  1. Study Details | NCT01277822 | Efficacy of Losartan + Amlodipine Compared to Amlodipine Alone in the Treatment of Uncontrolled High Blood Pressure (MK-0954F-399)
  2. Efficacy and safety of single-pill amlodipine/losartan versus losartan in patients with inadequately controlled hypertension after Losartan treatment - Frontiers
  3. Amlodipine - StatPearls (Mechanism and Pharmacokinetics Review)

Frequently Asked Questions (FAQ)

Common questions about Amlozaar (FAQ)

Q: Why did my doctor prescribe Amlozaar instead of Amlodipine alone?

Official information indicates that fixed-dose combination products like Amlozaar are typically prescribed when an adult patient's blood pressure is not adequately controlled by using a single medication, such as Amlodipine, by itself. Combining two agents, Amlodipine and Losartan, in one pill is also a recognized strategy to help optimize patient adherence to the prescribed regimen.


Q: Is Amlozaar a blood pressure medication or something else?

Amlozaar is classified as an antihypertensive agent, meaning its principal purpose is to lower and manage high blood pressure (hypertension). It is not indicated as a primary treatment for conditions like high cholesterol or diabetes.


Q: Does Amlozaar treat high blood pressure AND heart failure?

The medication is primarily indicated for high blood pressure. Regarding heart failure, official product information generally advises caution or does not recommend its use in patients with severe heart failure (NYHA Class IV) due to limited study data in that specific group.


Q: Does Amlozaar affect kidney function in the long term?

The Losartan component carries a risk of worsening existing kidney function, especially in individuals who already have renal impairment or volume depletion. For this reason, regulatory documents state that monitoring of kidney function, including markers like creatinine and BUN levels, is necessary during treatment.


Q: Is there a risk of low blood pressure (hypotension) with Amlozaar?

Yes, regulatory documents confirm that low blood pressure, or hypotension, is a documented risk associated with Amlozaar. This risk is particularly noted for individuals with volume depletion or salt imbalances. Severe hypotension is also listed as a contraindication for the Amlodipine component.


Q: Should I avoid certain foods or drinks while on Amlozaar?

Specifically, regulatory information advises against the use of potassium-containing salt substitutes or potassium supplements, as the Losartan component may lead to elevated potassium levels in the blood. Co-administration with alcohol may also result in additive hypotensive (blood pressure lowering) effects.


Q: Can I take heartburn medication (antacids) close to the time I take Amlozaar?

Regulatory documents mention that antacids, specifically those containing calcium carbonate, may decrease the overall effectiveness of the Amlodipine component in the combination pill. If taking antacids, it is noted that appropriate timing and potential monitoring should be discussed with a healthcare provider.


Q: Does Amlozaar cause weight gain or weight loss?

Clinical trial data for the Amlodipine component show that both weight gain and weight decrease have been reported as less common adverse effects in some subjects. These changes are noted in the official safety profile.


Q: How often should blood tests be done while on Amlozaar?

Official labeling recommends that patients should have their blood checked periodically. This monitoring is necessary to check serum potassium concentration and kidney function (using blood markers like creatinine), especially due to the effects of the Losartan component.


Q: Can Amlozaar cause fatigue or tiredness?

Yes, official safety information lists fatigue/asthenia and somnolence (drowsiness) as common adverse reactions experienced by patients taking this medication. These symptoms are sometimes reported as more frequently observed when treatment is first started.


Q: Why would someone need a combination pill like Amlozaar?

The medication is primarily intended for use in individuals whose high blood pressure is not adequately controlled by therapy with a single agent. The fixed-dose combination format is also officially recognized as a strategy to optimize patient adherence.


Q: Are there any long-term studies on the safety of Amlozaar?

Clinical studies included the collection of long-term data extending up to one year to track both the effectiveness and the patterns of side effects associated with continuous use. Researchers use this data to assess the sustained safety and tolerability of the fixed-dose combination.


Q: Does grapefruit interact negatively with Amlozaar?

Official documentation for the Amlodipine component states that consuming grapefruit or grapefruit juice may increase the levels of the drug in the bloodstream. Given the potential for variability, discussion regarding consumption and appropriate monitoring may be necessary.


Q: Can Amlozaar be taken in the morning or is evening better?

Official drug administration information states that Amlozaar may be taken at any time of day. The most important instruction is that the tablet should be taken at the same time each day for consistency. Timing may be determined by a healthcare provider to best fit a treatment schedule.


Q: Will Amlozaar affect my heart rate?

Yes, official adverse reaction reports include effects on heart rhythm. Side effects reported include palpitations (feeling a pounding heart), and there have been reports of changes in heart rate, including both tachycardia (fast heart rate) and bradycardia (slow heart rate).


Q: Can Amlozaar affect potassium levels in the blood?

Yes, the Losartan component is associated with the potential to increase potassium levels in the blood, a condition called hyperkalemia. For this reason, periodic monitoring of potassium levels is part of the treatment protocol, particularly for individuals with kidney impairment.


Q: Is Amlozaar a generic drug or brand name only?

The drug is a fixed-dose combination that contains two established generic medications: Amlodipine and Losartan. While it may be sold under various brand names, it is also available as a generic combination product.


Q: What is the difference between Amlozaar and medications ending in '-pril'?

The difference lies in how the drugs work. Amlozaar contains Losartan, which is an Angiotensin II Receptor Blocker (ARB). Medications ending in '-pril' (like Lisinopril) are Angiotensin-Converting Enzyme (ACE) Inhibitors. Both types affect the same blood pressure system, but ARBs block a hormone receptor directly, while ACE inhibitors block the enzyme that creates the hormone.


Q: Is a metallic taste in the mouth reported with Amlozaar?

Yes, taste changes, known as dysgeusia or taste perversion, have been reported in post-marketing experience with the Losartan component of the combination. This can sometimes be described by patients as a metallic taste in the mouth.

How should Amlozaar be stored and disposed of?

The storage and disposal of Amlozaar (Losartan/Amlodipine) must adhere strictly to the conditions specified in the medicine’s official regulatory labeling.

Storage Requirements

Category Official Constraints
Temperature Store at room temperature, typically between 20°C and 25°C (68°F and 77°F), and generally below 30 C
Protection Keep in the original container, tightly closed, and protect from light and moisture
Child Safety Must be kept out of the sight and reach of children and pets

Disposal Instructions

  • Do not use the medicine after the labeled expiry date.
  • Do not dispose of unused or expired Amlozaar by pouring it down a sink or flushing it down a toilet (wastewater).
  • Follow official disposal guidance: ask a pharmacist or use an approved drug take-back program or mail-back service where available.
  • If take-back options are not available, mix the tablets with an undesirable substance (like coffee grounds or dirt), place in a sealed bag, and throw it in the household trash, after scratching out all personal information on the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amlozaar found in:

A-Z Index: